Patients with non-cystic fibrosis (CF) bronchiectasis responded favorably to airway maintenance therapy using the Monaghan Medical’s Aerobika device, according to findings of a study published in the most recent issue of Academic Radiology.
This latest study adds to the growing base of evidence that demonstrates Monaghan’s drug-free Aerobika device is effective for lung health maintenance, the company said in a press release.
Researchers noted significant improvements in ventilation function for a number of bronchiectasis patients after three weeks of using the Aerobika device. There were no adverse events related to the use of the device reported during the study, according to Monaghan Medical.
There are three primary goals in the successful treatment of bronchiectasis:
Treat any underlying conditions and lung infections
Remove mucus from the lungs, and
“This most recent study just adds to the mounting clinical evidence that our Aerobika device is effective for patients with bronchiectasis, COPD, and related respiratory disease,” said Dominic Coppolo, MBA, RRT, FAARC, vice president Clinical Strategy and Development at Monaghan Medical. “We are always pleased to see real-world findings that demonstrate the efficacy of ourAerobika device in clearing mucus to improve lung function in patients with chronic bronchial ailments as well as high-risk COPD patients.”